ScholarLens Back to search
2011•Linchuang gandanbing zazhiRequires access

Therapeutic effects of 48-week telbivudine treatment in patients with cirrhosis caused by HBV

Huang Fe

Open publisher page 0 citations

Abstract

Objective To observe the therapeutic effects of 48-week telbivudine treatment in patients with cirrhosis caused by hepatitis B virus(HBV).Methods In this cohort study,93 patients with liver cirrhosis caused by HBV were divided into three groups randomly: telbivudine(LDT) group(n=32),lamivudine(LMV) group(n=31),and control group(n=30): conventional liver protection treatment.The course of treatment lasted 48 weeks.The virological and biochemical parameters,PT,hepatic fibrosis index and Child-Pugh score were observed at different time points during treatment.Results The HBV DNA levels in telbivudine group were significantly decreased.The negative rates of HBV DNA(500 copies/ml) were correspondingly and significantly higher than those in lamivudine group and control group(P0.05).At week 24 and 48,the negative rates of hepatitis B e antigen(HBeAg) and the rates of HBeAg/anti-HBe sero-conversion in telbivudine group were significantly higher than those in control group(P0.01).ALT,AST,total bilirubin,hepatic fibrosis index and Child-Pugh score were significantly improved in telbivudine group and lamivudine group after treatment(P0.05).Conclusion Telbivudine can rapidly and effectively inhibit HBV DNA replication and improve liver function,hepatic fibrosis index and Child-Pugh score in patients with liver cirrhosis caused by HBV.

About this research paper

What this paper is about

Objective To observe the therapeutic effects of 48-week telbivudine treatment in patients with cirrhosis caused by hepatitis B virus(HBV).Methods In this cohort study,93 patients with liver cirrhosis caused by HBV were divided into three groups randomly: telbivudine(LDT) group(n=32),lamivudine(LMV) group(n=31),and control group(n=30): conventional liver protection treatment.The course of treatment lasted 48 weeks.The virological and biochemical parameters,PT,hepatic fibrosis index and Child-Pugh score were observed at different time points during treatment.Results The HBV DNA levels in telbivudine group were significantly decreased.The negative rates of HBV DNA(500 copies/ml) were correspondingly and significantly higher than those in lamivudine group and control group(P0.05).At week 24 and 48,the negative rates of hepatitis B e antigen(HBeAg) and the rates of HBeAg/anti-HBe sero-conversion in telbivudine group were significantly higher than those in control group(P0.01).ALT,AST,total bilirubin,hepatic fibrosis index and Child-Pugh score were significantly improved in telbivudine group and lamivudine group after treatment(P0.05).Conclusion Telbivudine can rapidly and effectively inhibit HBV DNA replication and improve liver function,hepatic fibrosis index and Child-Pugh score in patients with liver cirrhosis caused by HBV.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the therapeutic effects of 48-week telbivudine treatment in patients with cirrhosis caused by hepatitis B virus(HBV).Methods In this cohort study,93 patients with liver cirrhosis caused by HBV were divided into three groups randomly: telbivudine(LDT) group(n=32),lamivudine(LMV) group(n=31),and control group(n=30): conventional liver protection treatment.The course of treatment lasted 48 weeks.The virological and biochemical parameters,PT,hepatic fibrosis index and Child-Pugh score were observed at different time points during treatment.Results The HBV DNA levels in telbivudine group were significantly decreased.The negative rates of HBV DNA(500 copies/ml) were correspondingly and significantly higher than those in lamivudine group and control group(P0.05).At week 24 and 48,the negative rates of hepatitis B e antigen(HBeAg) and the rates of HBeAg/anti-HBe sero-conversion in telbivudine group were significantly higher than those in control group(P0.01).ALT,AST,total bilirubin,hepatic fibrosis index and Child-Pugh score were significantly improved in telbivudine group and lamivudine group after treatment(P0.05).Conclusion Telbivudine can rapidly and effectively inhibit HBV DNA replication and improve liver function,hepatic fibrosis index and Child-Pugh score in patients with liver cirrhosis caused by HBV.

Key concepts: Telbivudine, Medicine, Lamivudine, Cirrhosis, Gastroenterology, HBeAg, Internal medicine, Hepatitis B

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Therapeutic effects of 48-week telbivudine treatment in patients with cirrhosis caused by HBV — Research Paper | ScholarLens